Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 0.67 |
| ▸ | AKT2 | P31751 | 9/20 | 0.63 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1939898 | 0.91 | AKT1 (1.00) | AKT1HTR2BAKT2 | |
| SCHEMBL1939361 | 0.91 | AKT1 (1.00) | AKT1HTR2BAKT2 | |
| SCHEMBL1939591 | 0.84 | AKT1 (0.71) | AKT1AKT2 | |
| SCHEMBL1939708 | 0.82 | AKT1 (0.75) | AKT1HTR2BAKT2PAX8 | |
| SCHEMBL1939418 | 0.82 | AKT1 (0.69) | AKT1AKT2 | |
| SCHEMBL1940177 | 0.82 | AKT1 (0.70) | AKT1AKT2 | |
| SCHEMBL1940506 | 0.80 | AKT1 (0.80) | AKT1HTR2BAKT2 | |
| SCHEMBL14501035 | 0.78 | HTR2B (0.77) | AKT1HTR2BAKT2PAX8 | |
| SCHEMBL1938575 | 0.78 | AKT1 (1.00) | AKT1AKT2PAX8 | |
| SCHEMBL1938617 | 0.78 | AKT1 (1.00) | AKT1AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622616-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2011-06-15 | — | — | EP | claimed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | claimed |
| EP-1622616-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| WO-2004096131-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2004-11-11 | — | — | WO | claimed |
| EP-1622616-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2011-06-15 | — | — | EP | disclosed |
| EP-1622616-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7579355-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579355-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
| EP-1622616-A2 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096131-A2 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043001-A1 | Inhibitors of akt activity | MTMR1, PIK3CA, PLK1 | AKT1 5/4885HTR2B 4294/4885AKT2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.